

Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF), Type of Formulation (Solids, Oral Liquids and Injectables), Type of Primary Packaging Used (Blister Packs, Glass / Plastic Bottles, Pouches / Sachets and Vials), Scale of Operation (Clinical and Commercial), Company Size (Small, Mid-sized and Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022 – 2035

<https://marketpublishers.com/r/LACD8D579090EN.html>

Date: February 2022

Pages: 305

Price: US\$ 4,799.00 (Single User License)

ID: LACD8D579090EN

Abstracts

The projected value of microbiome manufacturing market is expected to be valued at USD 23 million in 2022 and is anticipated to grow at a CAGR of 20% during the forecast period 2022-2035.

In light of the remarkable progress witnessed in the clinical development of microbiome-based live biotherapeutic products, it is foreseen that this emerging therapeutic sector will emerge as one of the most rapidly expanding markets within the pharmaceutical industry in the forthcoming years. Specifically, in 2020, a noteworthy 575 Investigational New Drug (IND) applications were submitted for these therapies, demonstrating a concerted effort to address a diverse range of disease indications such as autoimmune, gastrointestinal, infectious, metabolic, and oncological disorders. This surge in applications underscores the considerable scientific advancements achieved by these groundbreaking drug candidates.

Of particular significance is the imminent marketing approval expected in 2022 for SER-109, a microbiome-based therapy developed by Seres Therapeutics, by the United States Food and Drug Administration (FDA). This impending approval is poised to catalyze further growth within this sector. Additionally, the year 2020 witnessed the approval of over 640 patents specifically focused on microbiome therapeutics, coupled with a substantial investment of USD 1.5 billion dedicated to the development of microbiome-based therapeutic interventions.

Despite the considerable strides made in the development of live biotherapeutic products, challenges persist due to the intricacies of the manufacturing process. Concurrently, contemporary innovators express concerns regarding the limited availability of expertise, inadequate specialized infrastructure, the necessity for substantial capital investment, and the challenges associated with ensuring compliance with Good Manufacturing Practices (GMP) and capacity constraints.

To effectively address the technical and operational challenges highlighted above, numerous microbiome developers are increasingly relying on contract manufacturing organizations (CMOs). Presently, more than 50 entities engaged in the manufacturing of microbiome-related products operate either in-house or on a contractual basis. The current landscape of microbiome contract manufacturers is characterized by a high degree of fragmentation, featuring a blend of start-ups, mid-sized firms, and established players. Notably, in recent years, strategic alliances and acquisitions have been forged among various industry players, aiming to augment their respective service offerings and evolve into comprehensive one-stop-shops.

As stakeholders actively seek solutions to overcome existing challenges and prioritize innovation to enhance the microbiome production process, we anticipate substantial growth in the microbiome manufacturing market over the next decade.

Research Coverage

An introduction to the human microbiome, exploring various types of microbiome therapeutics. The chapter covers microbiota functions, insights from the Human Microbiome Project (HMP), manufacturing steps, challenges, and the increasing need for outsourcing. It concludes with factors for innovators to consider when choosing a Contract Manufacturing Organization (CMO) partner.

An overview of the microbiome contract manufacturing landscape, analyzing

25+ contract manufacturers based on parameters like establishment year, company size, service offerings, and more.

Detailed microbiome manufacturing facilities in key regions (North America, Europe, Asia-Pacific), including map representations and highlighting manufacturing hubs.

A company competitiveness analysis of microbiome manufacturing service providers, considering product and service strengths.

Detailed profiles of key industry players in North America, Europe, and Asia-Pacific, providing overviews, service portfolios, manufacturing facilities, and recent developments.

Recent developments in the microbiome manufacturing industry, covering partnerships, collaborations, mergers, acquisitions, and expansions from 2016 to 2021.

An in-depth analysis of completed, ongoing, and planned clinical studies of microbiome therapeutics, considering various parameters.

Installed capacity for manufacturing microbiome-based therapies, highlighting distribution by scale of operation, company size, and geographical regions.

An informed estimate of the annual clinical and commercial demand for microbiome therapeutics, considering ongoing and planned trials.

A qualitative analysis, outlining factors for microbiome therapeutics developers to consider when deciding to manufacture in-house or engage CMO services.

Key Market Companies

Capsugel

Jeneil Biotech

UAS Labs

Biose

Cerbios-Pharma

Inpac Probiotics

NIZO

Winlove Probiotics

BJP Laboratories

Contents

1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

- 2.1. Chapter Overview

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Concept of Human Microbiota and Microbiome
- 3.3. Overview of Gut Flora
 - 3.3.1. Role of Gut Flora in Healthy Individuals
 - 3.3.2. Factors Affecting Human Gut Flora
- 3.4. The Human Microbiome Project (HMP)
- 3.5. Overview of Microbiome Therapies
 - 3.5.1. Types of Microbiome Therapies
 - 3.5.1.1. Probiotics
 - 3.5.1.2. Prebiotics
 - 3.5.2. Applications of Microbiome Therapies
 - 3.5.3. Microbiome Therapies Supply Chain
- 3.6. Microbiome-based Product Manufacturing
 - 3.6.1. Key Steps Involved
 - 3.6.2. Associated Challenges
 - 3.6.3. Role of Contract Manufacturing Organizations (CMOs)
 - 3.6.4. Demand for Contract Manufacturing Services
- 3.7. Key Considerations while Selecting a Suitable CMO Partner

4. MARKET LANDSCAPE

- 4.1. Chapter Overview
- 4.2. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Market Landscape

Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF)...

- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Location of Headquarters
- 4.2.4. Analysis by Scale of Operation
- 4.2.5. Analysis by Type of Product Manufactured
- 4.2.6. Analysis by Type of Formulation
- 4.2.7. Analysis by Scale of Operation and Type of Formulation
- 4.2.8. Analysis by Type of Primary Packaging Used
- 4.2.9. Analysis by Type of Formulation and Type of Primary Packaging Used
- 4.2.10. Analysis by Type of Fermentation
- 4.2.11. Analysis by Type of Fermentation and Location of Headquarters
- 4.2.12. Analysis by Type of Service(s) Offered
- 4.2.13. Analysis by Number of Manufacturing Facilities
- 4.2.14. Analysis by Location of Manufacturing Facilities
- 4.3. Live Biotherapeutic Products and Microbiome In-House Manufacturers: Market Landscape
 - 4.3.1. Analysis by Year of Establishment
 - 4.3.2. Analysis by Company Size
 - 4.3.3. Analysis by Scale of Operation
 - 4.3.4. Analysis by Location of Headquarters
 - 4.3.5. Analysis by Location of Manufacturing Facilities

5. REGIONAL CAPABILITY ANALYSIS

- 5.1. Chapter Overview
- 5.2. Key Assumptions and Methodology
- 5.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in North America
- 5.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in Europe
- 5.5. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in Asia-Pacific

6. COMPANY COMPETITIVENESS ANALYSIS

- 6.1. Chapter Overview
- 6.2. Key Assumptions and Parameters
- 6.3. Methodology
- 6.4. Company Competitiveness: North America

- 6.5. Company Competitiveness: Europe
- 6.6. Company Competitiveness: Asia-Pacific
- 6.7. Capability Benchmarking of Top Microbiome Contract Manufactures

7. COMPANY PROFILES

- 7.1. Chapter Overview
- 7.2. CMOs Headquartered in North America
 - 7.2.1. Capsugel
 - 7.2.1.1. Company Overview
 - 7.2.1.2. Service Portfolio
 - 7.2.1.3. Facilities Dedicated to Microbiome Manufacturing
 - 7.2.1.4. Recent Developments and Future Outlook
 - 7.2.2. Jeneil Biotech
 - 7.2.2.1. Company Overview
 - 7.2.2.2. Service Portfolio
 - 7.2.2.3. Facilities Dedicated to Microbiome Manufacturing
 - 7.2.2.4. Recent Developments and Future Outlook
 - 7.2.3. UAS Labs
 - 7.2.3.1. Company Overview
 - 7.2.3.2. Service Portfolio
 - 7.2.3.3. Facilities Dedicated to Microbiome Manufacturing
 - 7.2.3.4. Recent Developments and Future Outlook
- 7.3. CMOs Headquartered in Europe
 - 7.3.1. Biose
 - 7.3.1.1. Company Overview
 - 7.3.1.2. Service Portfolio
 - 7.3.1.3. Facilities Dedicated to Microbiome Manufacturing
 - 7.3.1.4. Recent Developments and Future Outlook
 - 7.3.2. Cerbios-Pharma
 - 7.3.2.1. Company Overview
 - 7.3.2.2. Financial Information
 - 7.3.2.3. Service Portfolio
 - 7.3.2.4. Facilities Dedicated to Microbiome Manufacturing
 - 7.3.2.5. Recent Developments and Future Outlook
 - 7.3.3. Inpac Probiotics
 - 7.3.3.1. Company Overview
 - 7.3.3.2. Service Portfolio
 - 7.3.3.3. Facilities Dedicated to Microbiome Manufacturing

7.3.3.4. Recent Developments and Future Outlook

7.3.4. NIZO

7.3.4.1. Company Overview

7.3.4.2. Service Portfolio

7.3.4.3. Facilities Dedicated to Microbiome Manufacturing

7.3.4.4. Recent Developments and Future Outlook

7.3.5 Winclove Probiotics

7.3.5.1. Company Overview

7.3.5.2. Service Portfolio

7.3.5.3. Facilities Dedicated to Microbiome Manufacturing

7.3.5.4. Recent Developments and Future Outlook

7.4. CMOs Headquartered in Asia-Pacific and Rest of the World

7.4.1. BJP Laboratories

7.4.1.1. Company Overview

7.4.1.2. Service Portfolio

7.4.1.3. Facilities Dedicated to Microbiome Manufacturing

7.4.1.4. Recent Developments and Future Outlook

8. LIKELY PARTNER ANALYSIS

8.1. Chapter Overview

8.2. Scoring Criteria and Key Assumptions

8.3. Scope and Methodology

8.4. Key Potential Strategic Partners for Live Biotherapeutic Products and Microbiome Manufacturers

8.4.1. Likely Partner Opportunities in North America

8.4.2. Likely Partner Opportunities in Europe

8.4.3. Likely Partner Opportunities in Asia-Pacific

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS

9.1. Chapter Overview

9.2. Scope and Methodology

9.3. Microbiome Related Initiatives of Big Pharmaceutical Players

9.3.1. Analysis by Portfolio Diversity

9.3.2. Analysis by Phase of Development

9.3.3. Analysis by Type of Therapy

9.3.4. Analysis by Type of Drug Molecule

9.3.5. Analysis by Target Therapeutic Areas

9.4. Benchmark Analysis of Big Pharmaceutical Players

- 9.4.1. Spider Web Analysis: AbbVie
- 9.4.2. Spider Web Analysis: AstraZeneca
- 9.4.3. Spider Web Analysis: Bristol-Myers Squibb
- 9.4.4. Spider Web Analysis: Johnson and Johnson
- 9.4.5. Spider Web Analysis: Merck
- 9.4.6. Spider Web Analysis: Novartis
- 9.4.7. Spider Web Analysis: Novo Nordisk
- 9.4.8. Spider Web Analysis: Pfizer
- 9.4.9. Spider Web Analysis: Roche
- 9.4.10. Spider Web Analysis: Takeda Pharmaceutical

9.5. Concluding Remarks

10. RECENT DEVELOPMENTS AND INITIATIVES

10.1. Chapter Overview

10.2. Partnership Models

10.3. Live Biotherapeutic Products and Microbiome: Recent Partnerships and Collaborations

- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Year and Type of Partnership
- 10.3.4. Analysis by Type of Organization
- 10.3.5. Analysis by Type of Partnership and Type of Organization
- 10.3.6. Analysis by Target Therapeutic Area
- 10.3.7. Most Active Players: Analysis by Number of Partnerships
- 10.3.8. Analysis by Region
 - 10.3.8.1. Intracontinental and Intercontinental Agreements
 - 10.3.8.2. Local and International Agreements
- 10.3.9. Cumulative Year-wise Trend of Merger / Acquisition
- 10.3.10. Analysis by Type of Acquisition
- 10.3.11. Analysis by Key Value Drivers
- 10.3.12. Analysis by Year of Acquisition and Key Value Drivers

10.4. Live Biotherapeutic Products and Microbiome: Recent Expansions

- 10.4.1. Analysis by Year of Expansion
- 10.4.2. Analysis by Purpose of Expansion
- 10.4.3. Analysis by Year and Purpose of Expansion
- 10.4.4. Analysis by Scale of Operation
- 10.4.5. Analysis by Purpose of Expansion and Scale of Operation

10.4.6. Analysis by Region

10.4.6.1. Analysis by Location of Manufacturing Facility (Continent-wise)

10.4.6.2. Analysis by Location of Manufacturing Facility (Country-wise)

10.4.7. Analysis by Purpose of Expansion and Location of Manufacturing Facility

11. CLINICAL TRIAL ANALYSIS

11.1. Chapter Overview

11.2. Scope and Methodology

11.3. Live Biotherapeutic Products and Microbiome: Clinical Trial Analysis

11.3.1. Analysis by Trial Registration Year

11.3.2. Analysis by Trial Status

11.3.3. Analysis by Trial Phase

11.3.4. Analysis by Trial Registration Year and Trial Recruitment Status

11.3.5. Analysis by Trial Registration Year and Enrolled Patient Population

11.3.6. Analysis by Study Design

11.3.7. Most Active Players: Analysis by Number of Registered Trials

11.3.7. Emerging Focus Area

11.3.9. Analysis by Therapeutic Area

11.3.10. Geographical Analysis by Number of Registered Trials

11.3.11. Geographical Analysis by Enrolled Patient Population

12. CAPACITY ANALYSIS

12.1. Chapter Overview

12.2. Key Assumptions and Methodology

12.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Global Production Capacity

12.3.1. Analysis by Company Size

12.3.2. Analysis by Scale of Operation

12.3.3. Analysis by Region

12.3.3.1. Capacity Analysis: North America

12.3.3.2. Capacity Analysis: Europe

12.3.3.3. Capacity Analysis: Asia-Pacific

12.4. Concluding Remarks

13. DEMAND ANALYSIS

13.1. Chapter Overview

13.2. Scope and Methodology

13.3. Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing

13.4. Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing

13.4.1. Geographical Analysis of Clinical Demand

13.4.1.1. Clinical Demand in North America

13.4.1.2. Clinical Demand in Europe

13.4.1.3. Clinical Demand in Asia-Pacific and Rest of the World

13.4.2. Analysis of Clinical Demand by Trial Phase

13.5. Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing

13.6. Concluding Remarks

14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

14.1. Chapter Overview

14.2. Assumptions and Key Parameter

14.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Make versus Buy Decision Making

14.3.1. Scenario

14.3.2. Scenario

14.3.3. Scenario

14.3.4. Scenario

14.4. Concluding Remarks

15. CASE STUDY: LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT RESEARCH ORGANIZATIONS (CROS) AND DIETARY SUPPLEMENT MANUFACTURERS

15.1. Chapter Overview

15.2. Live Biotherapeutic Products and Microbiome CROs: Overall Market Landscape

15.2.1. Analysis by Year of Establishment

15.2.2. Analysis by Company Size

15.2.3. Analysis by Location of Headquarters

15.3. Microbiome Dietary Supplement Manufacturers: Overall Market Landscape

15.3.1. Analysis by Year of Establishment

15.3.2. Analysis by Company Size

15.3.3. Analysis by Location of Headquarters

16. MARKET FORECAST

16.1. Chapter Overview

16.2. Forecast Methodology

16.3. Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2022-2035

16.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Type of Product Manufactured

16.4.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs, 2022-2035

16.4.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs, 2022-2035

16.5. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Type of Formulation

16.5.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solid Formulations, 2022-2035

16.5.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Oral Liquids, 2022-2035

16.5.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Injectables, 2022-2035

16.5.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2022-2035

16.6. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Scale of Operation

16.6.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical Operations, 2022-2035

16.6.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial Operations, 2022-2035

16.7. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Company Size

16.7.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2022-2035

16.7.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2022-2035

16.7.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large Companies, 2022-2035

16.8. Microbiome Contract Manufacturing Market: Analysis by Geography

16.8.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market

in North America, 2022-2035

16.8.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
in Europe, 2022-2035

16.8.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market
in Asia-Pacific and Rest of the World, 2022-2035

16.9. Concluding Remarks

17. CONCLUSION

17.1. Chapter Overview

18. INTERVIEW TRANSCRIPTS

18.1. Chapter Overview

18.2. Traci Kyes, Vice President of Commercial Operations, Arranta Bio

18.2.1. Arranta Bio: Key Highlights

18.2.2. Interview Transcript

18.2. JP Benya, Vice President, Business Development, Assembly Biosciences

18.2.1. Assembly Biosciences: Key Highlights

18.2.2. Interview Transcript

18.3. Assaf Oron, Chief Business Officer, BiomX

18.3.1. BiomX: Key Highlights

18.3.2. Interview Transcript

18.4. Alexander Lin, Associate General Manager, Chung Mei Pharmaceutical

18.4.1. Chung Mei Pharmaceutical: Key Highlights

18.4.2. Interview Transcript

18.5. Debbie Pinkston, Vice President, Sales and Business Development, List

18.5.1. List Biological Laboratories: Key Highlights

18.5.2. Interview Transcript

18.6. Max Rosetto, Head of Business Development, Luina Bio

18.6.1. Luina Bio: Key Highlights

18.6.2. Interview Transcript

18.7. Gaurav Kaushik, Managing Director and Chief Executive Officer, Meteoric

18.7.1. Meteoric Biopharmaceuticals: Key Highlights

18.7.2. Interview Transcript

18.8. Veronika Oudova, Co-founder and Chief Executive Officer, S-Biomedic

18.8.1. S-Biomedic: Key Highlights

18.8.2. Interview Transcript

18.9. Nikole Kimes, Founder and Chief Executive Officer, Siolta Therapeutics

18.9.1. Siolta Therapeutics: Key Highlights

18.9.2. Interview Transcript

18.10. Alexander Segal, Vice President, Business Development, Universal

18.10.1. Universal Stabilization Technologies: Key Highlights

18.10.2. Interview Transcript

18.11. Rob Van Dijk, Business Development Manager, Wacker Biotech

18.11.1. Wacker Biotech: Key Highlights

18.11.2. Interview Transcript

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF), Type of Formulation (Solids, Oral Liquids and Injectables), Type of Primary Packaging Used (Blister Packs, Glass / Plastic Bottles, Pouches / Sachets and Vials), Scale of Operation (Clinical and Commercial), Company Size (Small, Mid-sized and Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022 – 2035

Product link: <https://marketpublishers.com/r/LACD8D579090EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LACD8D579090EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970